Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility Study: tDCS for Treatment of Refractory Status Epilepticus

NCT05934903 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT05934903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05934903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility Study: tDCS for Treatment of Refractory Status Epilepticus
Lead sponsor
Yale University
Phase
Not applicable
Overall status
Terminated
Start date
August 31, 2023
Completion date
March 31, 2025
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory status epilepticus, status epilepticus